Document ID: chunk:federal_register_of_legislation:F2025C00039:reg:73342
Version: federal_register_of_legislation:F2025C00039
Segment Type: reg
Provision Reference: reg 73342
Character Range: 15631–16293

73342              An in situ hybridisation (ISH) test of tumour tissue from a patient with metastatic adenocarcinoma of the stomach or gastro‑oesophageal junction, with documented evidence of human epidermal growth factor receptor 2 (HER2) overexpression by immunohistochemical (IHC) examination giving a staining intensity score of 2+ or 3+ on the same tumour tissue sample, requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to HER2 gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme are fulfilled.               315.40